Ping An Biomedical Holds Extraordinary General Meeting
Bitget2026/10/30 20:34- Ping An Biomedical shareholders ratified a 40-for-1 share consolidation effective October 23, 2026, at their October 29, 2026, extraordinary meeting.
- Shareholders approved increasing authorized share capital from US$312,500 to US$12.5 million, with adoption of fourth amended articles conditional on that increase.
- The meeting also ratified third amended articles reflecting the consolidation and approved general authorization to implement the resolutions.
- Further share consolidations of 10-for-1, 20-for-1, 50-for-1 or 80-for-1 won approval, subject to specified share-price triggers.
- New amended articles reflecting any further consolidation were approved, with adoption conditional on that consolidation taking effect.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October


SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
